PTC Therapeutics to Participate at Upcoming Investor Conference
Get Alerts PTCT Hot Sheet
Join SI Premium – FREE
SOUTH PLAINFIELD, N.J., Jan. 2, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the J.P. Morgan Healthcare Conference on Tuesday, January 8th at 5 p.m. PST.
The presentation will be webcast live on the Events and Presentations page under the investor relations section of PTC Therapeutics' website at www.ptcbio.com and will be archived for 2 weeks following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection.
About PTC Therapeutics, Inc.PTC is a science-led, global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need.
FOR MORE INFORMATION PLEASE CONTACT:
Media: | Investors: |
Jane Baj | Emily Hill |
+1 (908) 912-9167 | +1 (908) 912-9327 |
View original content:http://www.prnewswire.com/news-releases/ptc-therapeutics-to-participate-at-upcoming-investor-conference-300771885.html
SOURCE PTC Therapeutics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CGTN: How 'China Opportunity 2.0' offers growth potential for global businesses
- RF Passion, Craftsman’s Journey: Over 30 Years of Steadfast Dedication – Interview with Kinghelm Chief Engineer Mr. Qin hongxiang
- Hertz Announces Pricing of Upsized $350 Million of Exchangeable Senior First-Lien Secured PIK Notes
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share